Faculty Profile

Dr. Amir Faisal

Associate Professor

Department Of Biology

Dr. Amir Faisal received his PhD in Cell Biology from Friedrich Miescher Institute for Biomedical Research/University of Basel, Switzerland in 2004. During his PhD he identified novel roles for Shc protein, an important adaptor downstream of tyrosine kinases, in insulin signalling and cytoskeletal reorganization. He received his first postdoctoral training (2004-2008) in Protein Phosphorylation Laboratory at London Research Institute where he discovered that another adaptor protein, MyD88, couples Protein Kinase C epsilon to Toll like receptors during innate immunity. From 2008 to 2014, he worked at Cancer Therapeutics Unit of Institute of Cancer Research in Sutton first as postdoctoral fellow and later as senior scientist. He played an important role in progression of several drug discovery projects, one of which resulted in discovery of a pre-clinical development candidate that will undergo phase I clinical trials in 2016. After joining LUMS in August 2014, he has been establishing a cancer therapeutics lab at SBASSE.

TitlePublicationAuthorYear
ATLANTIS - Attractor Landscape Analysis Toolbox for Cell Fate Discovery and ReprogrammingScientific ReportsShah O.S., Chaudhary M.F.A., Awan H.A., Fatima F., Arshad Z., Amina B., Ahmed M., Hameed H., Furqan M., Khalid S., Faisal A., Chaudhary S.U.2018
Identification and characterization of SSE15206, a microtubule depolymerizing agent that overcomes multidrug resistanceScientific ReportsManzoor S., Bilal A., Khan S., Ullah R., Iftikhar S., Emwas A.-H., Alazmi M., Gao X., Jawaid A., Saleem R.S.Z., Faisal A.2018
Introduction of a Methyl Group Curbs Metabolism of Pyrido[3,4- d]pyrimidine Monopolar Spindle 1 (MPS1) Inhibitors and Enables the Discovery of the Phase 1 Clinical Candidate N2-(2-Ethoxy-4-(4-methyl-4 H-1,2,4-triazol-3-yl)phenyl)-6-methyl- N8-neopentylpyrido[3,4- d]pyrimidine-2,8-diamine (BOS172722)Journal of Medicinal ChemistryWoodward H.L., Innocenti P., Cheung K.-M.J., Hayes A., Roberts J., Henley A.T., Faisal A., Mak G.W.-Y., Box G., Westwood I.M., Cronin N., Carter M., Valenti M., De Haven Brandon A., O'Fee L., Saville H., Schmitt J., Burke R., Broccatelli F., Van Montfort R.L.M., Raynaud F.I., Eccles S.A., Linardopoulos S., Blagg J., Hoelder S.2018
CDK1 inhibition facilitates formation of syncytiotrophoblasts and expression of human Chorionic GonadotropinPlacentaUllah R., Dar S., Ahmad T., de Renty C., Usman M., DePamphilis M.L., Faisal A., Shahzad-ul-Hussan S., Ullah Z.2018
Aurora B prevents premature removal of spindle assembly checkpoint proteins from the kinetochore: A key role for Aurora B in mitosisOncotargetGurden M.D., Anderhub S.J., Faisal A., Linardopoulos S.2018
Nicotine exposure augments renal toxicity of 5-azacytidine through p66shc: Prevention by resveratrolAnticancer ResearchArany I., Hall S., Faisal A., Dixit M.2017
Characterisation of CCT271850, a selective, oral and potent MPS1 inhibitor, used to directly measure in vivo MPS1 inhibition vs therapeutic efficacyBritish Journal of CancerFaisal A., Mak G.W.Y., Gurden M.D., Xavier C.P.R., Anderhub S.J., Innocenti P., Westwood I.M., Naud S., Hayes A., Box G., Valenti M.R., De Haven Brandon A.K., O'Fee L., Schmitt J., Woodward H.L., Burke R., Vanmontfort R.L.M., Blagg J., Raynaud F.I., Eccles S.A., Hoelder S., Linardopoulos S.2017
Natural products from Cuscuta reflexa Roxb. with antiproliferation activities in HCT116 colorectal cell linesNatural Product ResearchRiaz M., Bilal A., Ali M.S., Fatima I., Faisal A., Sherkheli M.A., Asghar A.2017
Synthesis and evaluation of modified chalcone based p53 stabilizing agentsBioorganic and Medicinal Chemistry LettersIftikhar S., Khan S., Bilal A., Manzoor S., Abdullah M., Emwas A.-H., Sioud S., Gao X., Chotana G.A., Faisal A., Saleem R.S.Z.2017
Rapid Discovery of Pyrido[3,4-d]pyrimidine Inhibitors of Monopolar Spindle Kinase 1 (MPS1) Using a Structure-Based Hybridization ApproachJournal of Medicinal ChemistryInnocenti P., Woodward H.L., Solanki S., Naud S., Westwood I.M., Cronin N., Hayes A., Roberts J., Henley A.T., Baker R., Faisal A., Mak G.W.-Y., Box G., Valenti M., De Haven Brandon A., O'Fee L., Saville H., Schmitt J., Matijssen B., Burke R., Van Montfort R.L.M., Raynaud F.I., Eccles S.A., Linardopoulos S., Blagg J., Hoelder S.2016
7-(Pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine-based derivatives for kinase inhibition: Co-crystallisation studies with Aurora-A reveal distinct differences in the orientation of the pyrazole N1-substituentBioorganic and Medicinal Chemistry LettersBavetsias V., Perez-Fuertes Y., McIntyre P.J., Atrash B., Kosmopoulou M., O'Fee L., Burke R., Sun C., Faisal A., Bush K., Avery S., Henley A., Raynaud F.I., Linardopoulos S., Bayliss R., Blagg J.2015
Naturally occurring mutations in the MPS1 gene predispose cells to kinase inhibitor drug resistanceCancer ResearchGurden M.D., Westwood I.M., Faisal A., Naud S., Cheung K.-M.J., McAndrew C., Wood A., Schmitt J., Boxall K., Mak G., Workman P., Burke R., Hoelder S., Blagg J., Van Montfort R.L.M., Linardopoulos S.2015
Targeting the PPM1D phenotype; 2,4-bisarylthiazoles cause highly selective apoptosis in PPM1D amplified cell-linesBioorganic and Medicinal Chemistry LettersCheeseman M.D., Faisal A., Rayter S., Barbeau O.R., Kalusa A., Westlake M., Burke R., Swan M., Van Montfort R., Linardopoulos S., Jones K.2014
Structure-based design of orally bioavailable 1 h -Pyrrolo[3,2- C ]pyridine inhibitors of mitotic kinase monopolar spindle 1 (MPS1)Journal of Medicinal ChemistryNaud S., Westwood I.M., Faisal A., Sheldrake P., Bavetsias V., Atrash B., Cheung K.-M.J., Liu M., Hayes A., Schmitt J., Wood A., Choi V., Boxall K., Mak G., Gurden M., Valenti M., De Haven Brandon A., Henley A., Baker R., McAndrew C., Matijssen B., Burke R., Hoelder S., Eccles S.A., Raynaud F.I., Linardopoulos S., Van Montfort R.L.M., Blagg J.2013
Aurora isoform selectivity: Design and synthesis of imidazo[4,5- B ]pyridine derivatives as highly selective inhibitors of aurora-A kinase in cellsJournal of Medicinal ChemistryBavetsias V., Faisal A., Crumpler S., Brown N., Kosmopoulou M., Joshi A., Atrash B., Perez-Fuertes Y., Schmitt J.A., Boxall K.J., Burke R., Sun C., Avery S., Bush K., Henley A., Raynaud F.I., Workman P., Bayliss R., Linardopoulos S., Blagg J.2013
Optimization of imidazo[4,5- b ]pyridine-based kinase inhibitors: Identification of a dual FLT3/aurora kinase inhibitor as an orally bioavailable preclinical development candidate for the treatment of acute myeloid leukemiaJournal of Medicinal ChemistryBavetsias V., Crumpler S., Sun C., Avery S., Atrash B., Faisal A., Moore A.S., Kosmopoulou M., Brown N., Sheldrake P.W., Bush K., Henley A., Box G., Valenti M., De Haven Brandon A., Raynaud F.I., Workman P., Eccles S.A., Bayliss R., Linardopoulos S., Blagg J.2012
Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: A model for emerging clinical resistance patternsLeukemiaMoore A.S., Faisal A., De Castro D.G., Bavetsias V., Sun C., Atrash B., Valenti M., De Haven Brandon A., Avery S., Mair D., Mirabella F., Swansbury J., Pearson A.D.J., Workman P., Blagg J., Raynaud F.I., Eccles S.A., Linardopoulos S.2012
The aurora kinase inhibitor CCT137690 downregulates MYCN and sensitizes MYCN-amplified neuroblastoma in VivoMolecular Cancer TherapeuticsFaisal A., Vaughan L., Bavetsias V., Sun C., Atrash B., Avery S., Jamin Y., Robinson S.P., Workman P., Blagg J., Raynaud F.I., Eccles S.A., Chesler L., Linardopoulos S.2011
Cisplatin induces apoptosis through the ERK-p66shc pathway in renal proximal tubule cellsCancer LettersClark J.S., Faisal A., Baliga R., Nagamine Y., Arany I.2010
Structure-based design of imidazo[1,2-a]pyrazine derivatives as selective inhibitors of Aurora-A kinase in cellsBioorganic and Medicinal Chemistry LettersBouloc N., Large J.M., Kosmopoulou M., Sun C., Faisal A., Matteucci M., Reynisson J., Brown N., Atrash B., Blagg J., McDonald E., Linardopoulos S., Bayliss R., Bavetsias V.2010
Imidazo[4,5-b]pyridine derivatives as inhibitors of aurora kinases: Lead optimization studies toward the identification of an orally bioavailable preclinical development candidateJournal of Medicinal ChemistryBavetsias V., Large J.M., Sun C., Bouloc N., Kosmopoulou M., Matteucci M., Wilsher N.E., Martins V., Reynisson J., Atrash B., Faisal A., Urban F., Valenti M., De Haven Brandon A., Box G., Raynaud F.I., Workman P., Eccles S.A., Bayliss R., Blagg J., Linardopoulos S., McDonald E.2010
p66SHC-mediated mitochondrial dysfunction in renal proximal tubule cells during oxidative injuryAmerican Journal of Physiology - Renal PhysiologyArany I., Faisal A., Clark J.S., Vera T., Baliga R., Nagamine Y.2010
A cancer-associated Aurora a mutant is mislocalized and misregulated due to loss of interaction with TPX2Journal of Biological ChemistryBibby R.A., Tang C., Faisal A., Drosopoulos K., Lubbe S., Houlston R., Bayliss R., Linardopoulos S.2009
The regulated assembly of a PKCe complex controls the completion of cytokinesisNature Cell BiologySaurin A.T., Durgan J., Cameron A.J., Faisal A., Marber M.S., Parker P.J.2008
The scaffold MyD88 acts to couple protein kinase C?? to toll-like receptorsJournal of Biological ChemistryFaisal A., Saurin A., Gregory B., Foxwell B., Parker P.J.2008